Enveric Biosciences, Inc. 8-K

What Happened

• On March 27, 2026, Enveric Biosciences, Inc. (ENVB) announced a corporate update and reported its financial results for the fourth quarter and full year ended December 31, 2025 via a press release.
• The press release was furnished as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02: Results of Operations and Financial Condition).

Key Details

• Date of disclosure: March 27, 2026.
• Reporting periods covered: Quarter and year ended December 31, 2025.
• Disclosure format: Press release furnished as Exhibit 99.1 and incorporated by reference into the Form 8-K.
• Filing items: Item 2.02 (results of operations) and exhibit listing under Item 9.01.

Why It Matters

• The company’s Q4 and full-year 2025 earnings and corporate update are material for investors evaluating Enveric’s recent performance, revenue trends, cash position and near-term plans.
• The Form 8-K furnishes the press release but does not itself present the numeric results in the filing text; investors should review Exhibit 99.1 (the March 27, 2026 press release) for the detailed financial figures and any commentary on guidance, operations or strategic updates.